EMA clarifies definition of Type II quality variations in revised fee rules for pharma
This article was originally published in SRA
The European Medicines Agency has adopted revised rules on drug-related fees to clarify the definition of Type II quality variations and to explain the mechanism for compensating national competent authorities and inspectorates for their work at the agency1,2.
You may also be interested in...
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight guidance documents have been posted on the tracker since its last update.